Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

DelveInsight's Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

With renewed financial strength, WeightWatchers accelerates its transformation with the appointment of key executives including Dr. Kim Boyd as Chief Medical Officer The Company is advancing its first ...

DELAWARE, DE, UNITED STATES, July 4, 2025 /EINPresswire.com/ -- The global Attention Deficit Hyperactivity Disorder (ADHD) market is anticipated to reach USD 18.3 billion by 2025, as a result of ...

DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...